Research
Area 5
Hemotherapy-Hemostasis
Team manager
Ginés Escolar
(Hospital Clínic)
GESCOLAR(ELIMINAR)@clinic.ub.es
Strategic objectives
1. To study the basic mechanisms that regulate the function of blood cells and the interactions between them, with the vascular wall and with other cells.
2. To evaluate the congenital and acquired defects of hemostasis and their correction by means of drugs and/or transfusions.
3. To characterize in the laboratory hemorrhagic and thrombotic phenotypes and genotypes.
4. To analyze the efficacy and safety of new saving strategies in transfusions of blood components.
5. To develop and evaluate the efficacy of synthetic platelet substitutes.
6. Characterization of animal models of hemostasis, preferably in mice.
Main lines of research
1. Study of the mechanisms involved in the development of hemorrhagic and thrombotic diseases. Proteomic study of the determination of changes in the vascular tree and the different blood cells in thrombotic and hemorrhagic diseases.
2. Evaluation of the physiologic and pathologic implication of circulating and/or intraplatelet tissue factor in atherothrombosis.
3. Search for alternatives to platelet transfusion and development of potential synthetic platelet substitutes with the ability to potentiate the physiologic mechanisms of hemostasis.
4. New therapeutic measures in autoimmune diseases of an essentially humoral nature. ABO-incompatible kidney transplant as a model.
5. Evaluation of the participation of serotoninergic purinergic mechanisms in platelet functionalism. Study of the antithrombotic potential of pharmacologic inhibitors.
6. Role of the phenotype/genotype of fibrinolysis inhibitors and repercussion on global or specific functional tests in hemorrhagic and thrombotic disease.
7. Study of the vitamin-K dependent protein GAS6 in hemostasis and the vascular wall, using KO mice for this gene.